In This Article:
Over the last 7 days, the United States market has dropped 2.8%, yet it has risen by 24% over the past year, with earnings expected to grow by 15% annually in the coming years. In this context of fluctuating short-term performance and promising long-term growth prospects, identifying high-growth tech stocks involves looking for companies with strong innovation potential and solid financial fundamentals that can withstand market volatility.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Super Micro Computer | 24.13% | 24.28% | ★★★★★★ |
| Ardelyx | 22.86% | 54.70% | ★★★★★★ |
| Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
| Clene | 61.16% | 59.11% | ★★★★★★ |
| Alnylam Pharmaceuticals | 21.24% | 56.34% | ★★★★★★ |
| TG Therapeutics | 30.06% | 45.28% | ★★★★★★ |
| Blueprint Medicines | 22.63% | 55.38% | ★★★★★★ |
| Travere Therapeutics | 28.68% | 62.50% | ★★★★★★ |
| Seagen | 22.57% | 71.80% | ★★★★★★ |
| ImmunoGen | 26.00% | 45.85% | ★★★★★★ |
Click here to see the full list of 235 stocks from our US High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Natera
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Natera, Inc. is a diagnostics company that develops and commercializes molecular testing services globally, with a market cap of $20.90 billion.
Operations: The company focuses on the development and commercialization of molecular testing services, generating approximately $1.53 billion in revenue.
Natera, with its focus on genetic testing and liquid biopsies, exemplifies innovation in the high-growth tech sector. Despite being unprofitable, the company is forecasted to reverse this trend within three years, with earnings expected to surge by 58.5% annually. This growth trajectory is bolstered by a robust R&D commitment, evident from recent initiatives like the SAGITTARIUS clinical trial aimed at enhancing colon cancer treatment through personalized strategies. Moreover, strategic alliances such as the integration of MyOme's polygenic risk score into Natera's offerings underscore a forward-thinking approach to healthcare solutions that could redefine patient management in oncology and beyond.
-
Unlock comprehensive insights into our analysis of Natera stock in this health report.
-
Explore historical data to track Natera's performance over time in our Past section.
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pinterest, Inc. operates as a visual search and discovery platform both in the United States and internationally, with a market cap of approximately $19.60 billion.
Operations: The company generates revenue primarily from advertising services within its visual search and discovery platform, amounting to $3.47 billion. The business model focuses on leveraging user engagement to attract advertisers seeking targeted marketing opportunities.